A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with Losartan for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2017-04, Vol.12 (4), p.e0175717-e0175717
Hauptverfasser:	McPherson, Stuart, Wilkinson, Nina, Tiniakos, Dina, Wilkinson, Jennifer, Burt, Alastair D, McColl, Elaine, Stocken, Deborah D, Steen, Nick, Barnes, Jane, Goudie, Nicola, Stewart, Stephen, Bury, Yvonne, Mann, Derek, Anstee, Quentin M, Day, Christopher P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiotensin Angiotensin converting enzyme Angiotensin II Angiotensin II receptor blockers Angiotensin II Type 1 Receptor Blockers - therapeutic use Angiotensin-converting enzyme inhibitors Biology and Life Sciences Biopsy Care and treatment Clinical trials Diabetes Diabetes mellitus Dosage and administration Double-Blind Method Drug Administration Schedule Enzyme inhibitors Fatty liver Female Fibrosis Fibrosis - prevention & control Health aspects Health services Hospitals Humans Inflammation Liver Liver - drug effects Liver - pathology Liver cirrhosis Liver Cirrhosis - prevention & control Liver diseases Losartan - therapeutic use Male Medicine Medicine and Health Sciences Middle Aged Non-alcoholic Fatty Liver Disease - drug therapy Patients Peptidyl-dipeptidase A Placebos Quality of life Recruitment Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!